Scott Henry
Stock Analyst at Alliance Global Partners
(1.79)
# 3,054
Out of 4,711 analysts
59
Total ratings
43.14%
Success rate
-2.15%
Average return
Main Sectors:
Stocks Rated by Scott Henry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VVOS Vivos Therapeutics | Maintains: Buy | $8.25 → $6 | $4.98 | +20.48% | 4 | Nov 19, 2024 | |
| LPCN Lipocine | Initiates: Buy | $10 | $4.87 | +105.34% | 1 | Sep 24, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $2.75 | $0.89 | +210.42% | 1 | May 28, 2024 | |
| DERM Journey Medical | Initiates: Buy | $8.5 | $4.68 | +81.62% | 2 | Feb 16, 2024 | |
| RNXT RenovoRx | Initiates: Buy | $4 | $1.25 | +220.00% | 3 | Feb 2, 2024 | |
| FBIO Fortress Biotech | Maintains: Buy | $30 → $15 | $1.72 | +772.09% | 2 | Nov 29, 2023 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $12 | $1.34 | +795.52% | 2 | Oct 30, 2023 | |
| CSBR Champions Oncology | Maintains: Buy | $9 → $7.5 | $7.51 | -0.07% | 2 | Sep 22, 2023 | |
| DCTH Delcath Systems | Maintains: Buy | $10 → $13 | $11.01 | +18.07% | 4 | Aug 16, 2023 | |
| VKTX Viking Therapeutics | Maintains: Buy | $19 → $24 | $42.25 | -43.20% | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $114.64 | -21.49% | 9 | Dec 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 → $16 | $21.27 | -27.13% | 2 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $58 | $92.12 | -37.04% | 6 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $36 | $54.65 | -34.13% | 1 | Aug 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $1.64 | +570.73% | 3 | May 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $6 | $7.10 | -15.49% | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6,000 → $5,750 | $4.40 | +130,617.47% | 1 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.20 | - | 1 | Dec 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $6.18 | +13.27% | 3 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.61 | - | 5 | Apr 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.53 | - | 2 | Mar 26, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.38 | - | 1 | Nov 10, 2017 |
Vivos Therapeutics
Nov 19, 2024
Maintains: Buy
Price Target: $8.25 → $6
Current: $4.98
Upside: +20.48%
Lipocine
Sep 24, 2024
Initiates: Buy
Price Target: $10
Current: $4.87
Upside: +105.34%
Assertio Holdings
May 28, 2024
Initiates: Buy
Price Target: $2.75
Current: $0.89
Upside: +210.42%
Journey Medical
Feb 16, 2024
Initiates: Buy
Price Target: $8.5
Current: $4.68
Upside: +81.62%
RenovoRx
Feb 2, 2024
Initiates: Buy
Price Target: $4
Current: $1.25
Upside: +220.00%
Fortress Biotech
Nov 29, 2023
Maintains: Buy
Price Target: $30 → $15
Current: $1.72
Upside: +772.09%
Reviva Pharmaceuticals Holdings
Oct 30, 2023
Reiterates: Buy
Price Target: $12
Current: $1.34
Upside: +795.52%
Champions Oncology
Sep 22, 2023
Maintains: Buy
Price Target: $9 → $7.5
Current: $7.51
Upside: -0.07%
Delcath Systems
Aug 16, 2023
Maintains: Buy
Price Target: $10 → $13
Current: $11.01
Upside: +18.07%
Viking Therapeutics
May 3, 2023
Maintains: Buy
Price Target: $19 → $24
Current: $42.25
Upside: -43.20%
Dec 23, 2022
Maintains: Buy
Price Target: $85 → $90
Current: $114.64
Upside: -21.49%
Aug 24, 2022
Downgrades: Neutral
Price Target: $10 → $16
Current: $21.27
Upside: -27.13%
Aug 3, 2021
Maintains: Neutral
Price Target: $55 → $58
Current: $92.12
Upside: -37.04%
Aug 2, 2021
Maintains: Buy
Price Target: $32 → $36
Current: $54.65
Upside: -34.13%
May 12, 2021
Maintains: Buy
Price Target: $9 → $11
Current: $1.64
Upside: +570.73%
Feb 26, 2021
Maintains: Buy
Price Target: $4 → $6
Current: $7.10
Upside: -15.49%
Feb 16, 2021
Maintains: Buy
Price Target: $6,000 → $5,750
Current: $4.40
Upside: +130,617.47%
Dec 4, 2020
Downgrades: Neutral
Price Target: n/a
Current: $0.20
Upside: -
Nov 11, 2020
Upgrades: Buy
Price Target: $7
Current: $6.18
Upside: +13.27%
Apr 18, 2019
Upgrades: Buy
Price Target: n/a
Current: $0.61
Upside: -
Mar 26, 2018
Downgrades: Neutral
Price Target: n/a
Current: $0.53
Upside: -
Nov 10, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.38
Upside: -